REG - OptiBiotix Health - Director's Dealing

OptiBiotix HealthAnnouncement

28/08/2019 10:00

RNS Number : 3997K
OptiBiotix Health PLC
28 August 2019
 


28 August 2019
OptiBiotix Health plc
("OptiBiotix" or the "Company")
 
Director's Dealing
 
OptiBiotix Health plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol, diabetes and skin care, announces that it received notification  today that Frédéric Narbel, a Director of the Company, acquired 17,000 ordinary shares in the Company today, representing 0.02% of the Company's issued share capital, at a price of 50 pence per share.
 
Following the transaction, Mr Narbel is interested in 29,000 ordinary shares in the Company, representing 0.03% of the Company's issued share capital.
 
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 and the person who arranged for release of this announcement on behalf of the Company was Stephen O'Hara, Chief Executive.
 
For further information, please contact:
 



OptiBiotix Health plc


www.optibiotix.com




Stephen O'Hara, Chief Executive


Contact via Walbrook below














Cairn Financial Advisers LLP (NOMAD)


Tel: 020 7213 0880




Liam Murray / Jo Turner / Ludovico Lazzaretti


















finnCap (Broker)


Tel: 020 7220 0500




Geoff Nash / Kate Bannatyne (Corporate Finance)








Camille Gochez (Corporate Broking)


 








 




goetzpartners securities Limited


Tel: 0203 859 7725




Ulrich Kinzel 


















Walbrook PR Ltd


Mob: 07876 741 001




Anna Dunphy












 
About OptiBiotix - www.optibiotix.com 
OptiBiotix Health plc (AIM: OPTI), which was formed in March 2012, brings science to the development of compounds which modify the human microbiome - the collective genome of the microbes in the body - in order to prevent and manage human disease and promote wellness. 
 
OptiBiotix has an extensive R&D program working with leading academics in the development of microbial strains, compounds, and formulations which are used as active ingredients and supplements. More than twenty international food and healthcare supplement companies have signed agreements with OptiBiotix to incorporate their human microbiome modulators into a wide range of food products and drinks.
 
OptiBiotix is also developing its own range of consumer supplements and health products. The Company's current areas of focus include obesity, cardiovascular health, and diabetes. 
 
 
 



Notification of a Transaction pursuant to Article 19(1) of Regulation (EU) No. 596/2014




1


Details of the person discharging managerial responsibilities/person closely associated




a.


Name


Frédéric André Narbel




2


Reason for notification








a.


Position/Status


Director of the Company




b.


Initial notification/
Amendment


Initial Notification




3


Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor




a.


Name


OptiBiotix Health Plc




b.


LEI


213800UKYQFT941QHS14




4


Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted




a.


Description of the financial instrument, type of instrument



Identification Code


17,000 ordinary shares of 2p each



 
ISIN: GB00BP0RTP38




b.


Nature of the transaction


Purchase of 17,000 ordinary shares in the Company
 




c.


Price(s) and volume(s)




























Price(s) per share


Volume(s)








50p


17,000








 
 




e.


Date of the transaction


28 August 2019




f.


Place of the transaction


London Stock Exchange, AIM



 
 
 
 
 




This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHGIGDIISDBGCI